Stockreport

Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) , arriving at a moment when the market had [Read more]